NCT07544446 What Impact Does an Initial Psycho-oncological Contact Have on People With Cancer?
| NCT ID | NCT07544446 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lindenhofgruppe AG |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 148 participants |
| Start Date | 2026-08-25 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 148 participants in total. It began in 2026-08-25 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
When diagnosed with cancer, patients or their relatives may, if they wish, on the recommendation of the treatment team and/or in cases of high stress, seek psycho-oncological support. This study investigates whether an initial consultation with a psycho-oncological specialist reduces anxiety and depression, improves quality of life, and whether patients subsequently make greater use of support services. Participants will be randomised, meaning they will be assigned to groups at random to ensure that the results are comparable. In the intervention group, participants will receive a detailed initial consultation with a psycho-oncology specialist and standard treatment. In the control group, participants receive standard treatment. To gather results, questionnaires are administered at regular intervals (at the start, after 3 and 6 months). The study lasts a total of 6 months. The study was developed by patients. It is being conducted simultaneously at several hospitals.
Eligibility Criteria
Inclusion Criteria: * Patients with an oncological disease diagnosed within the last 3 months with planned or ongoing systemic oncologic treatment (e.g. chemotherapy, immunotherapy, hormone therapy) or a planned or ongoing radiotherapy * Patient is ≥18 years of age and legally competent * Patients must have understood and signed the study information and the informed consent form * Patients are willing and able to complete scheduled follow-up evaluations / questionnaires as described in the informed consent * No previous contact with psycho-oncological services Exclusion Criteria: * Documented severe functional impairment according to the ECOG Performance Status (ECOG 3-4) * Patients receiving or planned to receive treatments associated with a severe risk of toxicity (e.g., CAR-T cell therapy, myeloablative therapy) * Insufficient language skills in German * Inability to give informed consent * Refusal to participate in the study, unsigned informed consent
Contact & Investigator
Janine Antonov, PhD, eMBA
STUDY CHAIR
Forschungszentrum Lindenhofgruppe
Frequently Asked Questions
Who can join the NCT07544446 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07544446 currently recruiting?
Yes, NCT07544446 is actively recruiting participants. Contact the research team at janine.antonov@lindenhofgruppe.ch for enrollment information.
Where is the NCT07544446 trial being conducted?
This trial is being conducted at Basel, Switzerland, Bern, Switzerland, Bern, Switzerland, Horgen, Switzerland and 1 additional location.
Who is sponsoring the NCT07544446 clinical trial?
NCT07544446 is sponsored by Lindenhofgruppe AG. The principal investigator is Janine Antonov, PhD, eMBA at Forschungszentrum Lindenhofgruppe. The trial plans to enroll 148 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.